Comparative Pharmacology
Head-to-head clinical analysis: CORDRAN N versus LOCOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORDRAN N versus LOCOID.
CORDRAN N vs LOCOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cordran N contains flurandrenolide, a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive actions by inducing phospholipase A2 inhibitory proteins (lipocortins) and modulating gene expression; neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
Apply sparingly to affected area 2-3 times daily. Use for no longer than 2 weeks.
Topical: Apply a thin layer to affected area once or twice daily. Maximum: 30-60 g per week. Not for use >2 consecutive weeks or on >50% of body surface.
None Documented
None Documented
Approximately 1-2 hours. Short half-life consistent with topical use; systemic exposure minimal with proper application.
Terminal elimination half-life: 30-40 hours; clinically significant for once-daily dosing and prolonged action
Primarily renal (biliary/fecal minimal). Unchanged drug and glucuronide metabolites excreted in urine.
Renal (approximately 60-70%) as conjugated metabolites; biliary/fecal (approximately 20-30%)
Category C
Category C
Topical Corticosteroid + Antibiotic
Topical Corticosteroid